Cepheid's Product Sales up 2 Percent in Q2

Jul 30, 2009

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market on Thursday that its total revenues fell around 3 percent, but its product sales were up 2 percent, for the second quarter of 2009.

The Sunnyvale, Calif.-based molecular diagnostics firm brought in total revenues of $41 million for the three months ended June 30, compared to $42.1 million for the second quarter of 2008. Its product sales increased to $39.6 million from $39 million, while "other" revenues fell to $1.5 million from $3.1 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Not a Unique Challenge Anymore

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Case Goes On

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

The Very Old, Very Young, and Very Talented

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

This Week in PLOS

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.

Featured White Papers

Point of Care Testing Using Smartphone Diagnostic Readers - Download FAQ Guide

Contract Manufacturing in Biotech: Turning Your Supply Chain Into a Competitive Differentiator

The Foundry Model is Coming to Molecular Diagnostics, Courtesy of the Semiconductor Industry

Aug

27

Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep

18

Featured Webinar

Validation and Internal QC of Clinical NGS to Support an Accredited Diagnostic Workflow

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.

Main menu